Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03524612 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
A Phase 2 study of Immune Thrombocytopenic Purpura (ITP), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT03524612 is a Phase 2 study of Immune Thrombocytopenic Purpura (ITP) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 105 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT03524612, a Phase 2 study of Immune Thrombocytopenic Purpura (ITP), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with steroids.
Conditions Studied
Interventions
- DRUG eltrombopag
Study Locations (20)
Other
- Novartis Investigative Site - Linz
- Novartis Investigative Site - Caen
- Novartis Investigative Site - Pessac
- Novartis Investigative Site - Athens
- Novartis Investigative Site - Pátrai
- Novartis Investigative Site - Mexico City
- Novartis Investigative Site - Muscat
- Novartis Investigative Site - Moscow
- Novartis Investigative Site - Saint Petersburg
New York
- Hematology Oncology Association of Rockland - Nyack
Ohio
- Case Western Reserve - Cleveland
Estado de Bahia
- Novartis Investigative Site - Salvador
Rio de Janeiro
- Novartis Investigative Site - Rio de Janeiro
São Paulo
- Novartis Investigative Site - São Paulo
Región de la Araucanía
- Novartis Investigative Site - Temuco
Región de Valparaíso
- Novartis Investigative Site - Viña del Mar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2018-11-02 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03524612
The ClinicalTrials.gov registry entry for NCT03524612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Thrombocytopenic Purpura (ITP) appearing as the primary indexed condition, and to 1 intervention - of which eltrombopag is the first listed.
NCT03524612 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT03524612 about?
NCT03524612 is a clinical study titled "A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP". The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with steroids.
What is the current status of trial NCT03524612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2018-11-02. Estimated completion is 2022-10-03.
What conditions does trial NCT03524612 study?
This clinical trial studies the following conditions: Immune Thrombocytopenic Purpura (ITP).
What interventions are being tested in trial NCT03524612?
The interventions under investigation include: eltrombopag (DRUG).
Who is sponsoring clinical trial NCT03524612?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03524612 being conducted?
This trial has 20 study locations across New York, Ohio, Estado de Bahia, Rio de Janeiro, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenic Purpura (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.